Groupama Asset Managment Acquires 191,887 Shares of Boston Scientific Co. (NYSE:BSX)

Groupama Asset Managment raised its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 20.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,143,931 shares of the medical equipment provider's stock after buying an additional 191,887 shares during the period. Boston Scientific comprises about 0.8% of Groupama Asset Managment's investment portfolio, making the stock its 25th biggest holding. Groupama Asset Managment owned 0.08% of Boston Scientific worth $102,588,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. D.A. Davidson & CO. increased its position in Boston Scientific by 3.2% in the 3rd quarter. D.A. Davidson & CO. now owns 10,945 shares of the medical equipment provider's stock worth $917,000 after purchasing an additional 342 shares during the last quarter. Glenmede Trust Co. NA increased its holdings in Boston Scientific by 19.0% in the third quarter. Glenmede Trust Co. NA now owns 20,463 shares of the medical equipment provider's stock worth $1,715,000 after buying an additional 3,261 shares during the last quarter. CreativeOne Wealth LLC raised its position in Boston Scientific by 62.0% during the third quarter. CreativeOne Wealth LLC now owns 4,478 shares of the medical equipment provider's stock valued at $375,000 after acquiring an additional 1,714 shares in the last quarter. Rockefeller Capital Management L.P. lifted its stake in Boston Scientific by 10.6% in the third quarter. Rockefeller Capital Management L.P. now owns 137,964 shares of the medical equipment provider's stock valued at $11,536,000 after acquiring an additional 13,268 shares during the last quarter. Finally, Icon Wealth Advisors LLC bought a new stake in Boston Scientific in the third quarter worth approximately $100,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Insider Activity

In other news, EVP John Bradley Sorenson sold 1,201 shares of the company's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $106.31, for a total value of $127,678.31. Following the sale, the executive vice president now owns 25,443 shares of the company's stock, valued at approximately $2,704,845.33. This represents a 4.51 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Daniel J. Brennan sold 67,333 shares of Boston Scientific stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $105.24, for a total transaction of $7,086,124.92. Following the transaction, the chief financial officer now directly owns 225,808 shares of the company's stock, valued at $23,764,033.92. This represents a 22.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 133,183 shares of company stock worth $13,948,476. Company insiders own 0.50% of the company's stock.

Boston Scientific Stock Performance

BSX traded down $8.73 during trading on Friday, reaching $89.78. 22,572,180 shares of the company's stock were exchanged, compared to its average volume of 6,188,157. The company has a market capitalization of $132.78 billion, a P/E ratio of 71.82, a PEG ratio of 2.79 and a beta of 0.77. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. The business has a 50 day moving average price of $101.90 and a 200 day moving average price of $93.63. Boston Scientific Co. has a fifty-two week low of $66.80 and a fifty-two week high of $107.17.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. As a group, analysts predict that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Analyst Ratings Changes

BSX has been the topic of a number of recent research reports. Stifel Nicolaus raised their price target on shares of Boston Scientific from $100.00 to $115.00 and gave the company a "buy" rating in a report on Thursday, February 6th. Royal Bank of Canada raised their target price on Boston Scientific from $105.00 to $116.00 and gave the company an "outperform" rating in a report on Thursday, February 6th. TD Cowen boosted their price target on Boston Scientific from $100.00 to $110.00 and gave the stock a "buy" rating in a research report on Thursday, December 12th. Canaccord Genuity Group increased their price objective on Boston Scientific from $98.00 to $101.00 and gave the company a "buy" rating in a report on Monday, December 9th. Finally, UBS Group boosted their target price on Boston Scientific from $105.00 to $130.00 and gave the stock a "buy" rating in a report on Friday, February 7th. Two investment analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $108.91.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.